Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-Dose vs Two-Dose Dalbavancin in ABSSSI
NCT02127970Phase 3Completed
- Sponsor
- Allergan
- Start
- Apr 2014
- Primary completion
- Mar 2015
- Modality
- Peptides, Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of dalbavancin in acute bacterial skin and skin structure infection (ABSSSI), sponsored by Allergan. Started Apr 2014; status: completed.
02
Drugs
dalbavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT02127970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02127970.